https://www.live-feeds.com/feed/the-surprising-reason-this-biotech-just-plummeted-71Continuously updated, source-cited coverage. https://www.live-feeds.com/feed/the-surprising-reason-this-biotech-just-plummeted-71https://www.live-feeds.com/feed/the-surprising-reason-this-biotech-just-plummeted-71#u44936Tue, 18 Aug 2026 18:05:11 +0000EyePoint shares dropped between 69% and 71% following the failure of a late-stage clinical trial for DURAVYU 2.7mg. The drug targets wet age-related macular degeneration (AMD). The company released topline data from LUGANO, the first of two pivotal Phase 3 trials. While the results disappointed investors and caused a stock spiral, EyePoint maintains that the treatment still shows promise. The failure occurs during a competitive race to develop next-generation treatments for AMD.Why it mattersWet AMD is a leading cause of vision loss in older adults. EyePoint is competing in a high-stakes biote